Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dr. Ross on the Role of the Microbiome in CRC

August 24th 2022

Howard M. Ross, MD, discusses the role of the microbiome colorectal cancer.

Dr. Kozuch on the Role of ctDNA Following Surgery in CRC

August 24th 2022

Peter Kozuch, MD, discusses the role of circulating tumor DNA in colorectal cancer.

Concurrent Galunisertib and Neoadjuvant Chemoradiotherapy Improves CR Rates in Rectal Cancer

August 19th 2022

The addition of galunisertib to neoadjuvant chemoradiotherapy improved complete response rates in patients with locally advanced rectal cancer, according to findings from a phase 2 study.

Panitumumab Plus mFOLFOX6 Improves Survival in RAS Wild-Type mCRC

August 12th 2022

Treatment with frontline panitumumab and mFOLFOX6 led to a significant improvement in overall survival, plus higher response rates and R0 resection rates, compared with bevacizumab and mFOLFOX6 in patients with RAS wild-type metastatic colorectal cancer.

Fruquintinib Plus BSC Improves OS Over BSC Alone in Refractory Metastatic Colorectal Cancer

August 8th 2022

The addition of fruquintinib to best supportive care improved overall survival compared with BSC alone in patients with metastatic colorectal cancer who progressed on standard chemotherapy and relevant biologic agents, and who had progressed on or were intolerant to trifluridine/tipiracil and/or regorafenib.

Advice for Providers Treating Metastatic Colorectal Cancer

August 3rd 2022

Experts provide advice for providers treating patients with metastatic colorectal cancer and highlight exciting potential combination treatments on the horizon.

Novel Therapies in HER2-Amplified Metastatic Colorectal Cancer

August 3rd 2022

Dr Andrea Cercek reviews key clinical trials in HER2-amplified colorectal cancer treatment and considers how the approval of new therapies will impact the current treatment landscape.

Research Reflections: Subbiah Reviews Striking ASCO 2022 Data Across Oncology

August 1st 2022

Dr Subbiah discusses research from the 2022 ASCO Annual Meeting, including phase 2 data (NCT04165772) in mismatch repair–deficient, locally advanced rectal cancer; findings from DESTINY-Breast04 (NCT03734029) in HER2-low unresectable and/or metastatic breast cancer; a first-in-human study (NCT04585750) in TP53-mutant advanced solid tumors; and data from LIBRETTO-001 (NCT03157128) in RET fusion–positive solid tumors.

FDA Lifts Clinical Hold on KEYNOTE-B79 Trial Evaluating CAR T-cell Therapy CYAD-101 in Metastatic CRC

August 1st 2022

The FDA has lifted a clinical hold on the phase 1b KEYNOTE-B79 trial, which is evaluating the safety and clinical activity of CYAD-101 given concurrently with FOLFOX and followed by pembrolizumab in patients with unresectable metastatic colorectal cancer.

Sylvester Experts Explain the Most Promising Advances in Cancer Research and Treatment Presented at ASCO 2022

July 28th 2022

Cancer experts at the Sylvester Comprehensive Cancer Center: Annual Oncology Update shared important progress across a wide range of cancers — prostate cancer, breast cancer, colon cancer, and more — that was presented at the American Society of Clinical Oncology 2022 Annual Meeting, the largest gathering of cancer clinicians and scientists in the United States.

Primary Analysis of MOUNTAINEER: A Phase 2 Study of Tucatinib and Trastuzumab for HER2-positive mCRC

July 28th 2022

Dr Tanios Bekaii-Saab reviews data from the MOUNTAINEER trial on combination tucatinib/trastuzumab in patients with HER2-positive metastatic colorectal cancer.

Dr. Hays on the Importance of Clinical Trials in CRC

July 26th 2022

John L. Hays, MD, PhD, discusses the importance of clinical trials in colorectal cancer.

Dr. Strickler on the Rationale of Examining Tucatinib with Trastuzumab in HER2+ CRC

July 25th 2022

John H. Strickler, MD, discusses the rationale of tucatinib plus trastuzumab in HER2-positive colorectal cancer.

Treatment Options after Disease Progression in Metastatic Colorectal Cancer

July 22nd 2022

Andrea Cercek, MD, explains the potential treatment options for metastatic colorectal cancer after disease progression.

Individualizing Therapy in HER2+ Metastatic Colorectal Cancer

July 22nd 2022

Dr Jaclyn Hechtman presents the profile of a patient with HER2+ metastatic colorectal cancer and has a conversation with Dr Andrea Cercek on how to personalize frontline therapy selection in each patient.

The Future of Molecular Testing in Colorectal Cancer

July 13th 2022

A look at how the molecular testing landscape in colorectal cancer is evolving.

Challenges and Barriers to Colorectal Cancer Molecular Testing

July 13th 2022

Drs Hechtman and Cercek discuss how practice setting affects molecular testing options and the barriers patients face in receiving testing.

Dr. Ross on the Rise of Colon and Rectal Cancer in Young Patients

July 12th 2022

Howard M. Ross, MD, discusses the increase in colon and rectal cancer in young patients.

Dr. Hays on Treatment Options in HER2-Positive CRC

July 11th 2022

John L. Hays, MD, PhD, discusses expanding treatment options for HER2-positive colorectal cancer.

Short Course of Oxaliplatin/Fluoropyrimidine Noninferior for DFS, Neuropathy in High-Risk CRC

July 11th 2022

A 3-month course of oxaliplatin produced disease-free survival noninferior to a 6-month course in patients with high-risk stage II and III colorectal cancer.